By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company RenovoRx, Inc.

RenovoRx, Inc. (RNXT)

NASDAQ Currency in USD
$1.24
+$0.07
+5.98%
Last Update: 11 Sept 2025, 20:00
$45.44M
Market Cap
-3.47
P/E Ratio (TTM)
Forward Dividend Yield
$0.75 - $1.69
52 Week Range

RNXT Stock Price Chart

Explore RenovoRx, Inc. interactive price chart. Choose custom timeframes to analyze RNXT price movements and trends.

RNXT Company Profile

Discover essential business fundamentals and corporate details for RenovoRx, Inc. (RNXT) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

26 Aug 2021

Employees

10.00

CEO

Shaun R. Bagai

Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RNXT Financial Timeline

Browse a chronological timeline of RenovoRx, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 13 May 2026

Upcoming earnings on 12 Nov 2025

EPS estimate is -$0.08.

Earnings released on 14 Aug 2025

EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $422.00K , beating expectations by +38.82%.

Earnings released on 15 May 2025

EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $197.00K , beating expectations by +7.46%.

Earnings released on 31 Mar 2025

EPS came in at -$0.12 surpassing the estimated -$0.13 by +7.69%, while revenue for the quarter reached $43.00K , missing expectations by -74.33%.

Earnings released on 13 Nov 2024

EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%.

Earnings released on 13 Aug 2024

EPS came in at -$0.10 matching the estimated -$0.10.

Earnings released on 10 May 2024

EPS came in at -$0.07 surpassing the estimated -$0.14 by +50.00%.

Earnings released on 1 Apr 2024

EPS came in at -$0.17 surpassing the estimated -$0.30 by +43.33%.

Earnings released on 13 Nov 2023

EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%.

Earnings released on 16 Aug 2023

EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%.

Earnings released on 15 May 2023

EPS came in at -$0.36 falling short of the estimated -$0.25 by -44.00%.

Earnings released on 2 Mar 2023

EPS came in at -$0.23 surpassing the estimated -$0.26 by +11.54%.

Earnings released on 14 Nov 2022

EPS came in at -$0.24 surpassing the estimated -$0.27 by +11.11%.

Earnings released on 15 Aug 2022

EPS came in at -$0.29 falling short of the estimated -$0.26 by -11.54%.

Earnings released on 16 May 2022

EPS came in at -$0.33 falling short of the estimated -$0.25 by -32.00%.

Earnings released on 30 Mar 2022

EPS came in at -$0.12 surpassing the estimated -$0.18 by +33.33%.

Earnings released on 15 Nov 2021

EPS came in at -$0.27 falling short of the estimated -$0.21 by -28.57%.

Earnings released on 27 Aug 2021

EPS came in at -$0.08 .

Earnings released on 31 Mar 2021

EPS came in at -$0.07 .

Earnings released on 31 Dec 2020

EPS came in at -$0.05 .

Earnings released on 30 Sept 2020

EPS came in at -$0.07 .

RNXT Stock Performance

Access detailed RNXT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run